MAHA advocates are skeptical of President Donald Trump's deal to lower drug prices for GLP-1 anti-obesity drugs.

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly ...

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight ...

Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that’s not necessarily what you pay.

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...